Citigroup’s Aligos Therapeutics ALGS Stock Holding History

Citigroup’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4K	Buy	+1,808	New	+$11.2K	﹤0.01%	5240
2026 Q1	–	Sell	-1	Closed	-$9	–	5919
2025 Q4	$9	Buy	+1	New	+$9	﹤0.01%	5814
2023 Q1	–	Sell	-3	Closed	-$81	–	5463
2022 Q4	$81	Sell	3 -20	-87%	-$504	﹤0.01%	5646
2022 Q3	$1K	Sell	23 -41	-64%	-$1.36K	﹤0.01%	5601
2022 Q2	$2K	Sell	64 -214	-77%	-$7.27K	﹤0.01%	5849
2022 Q1	$15K	Sell	278 -23	-8%	-$1.84K	﹤0.01%	5301
2021 Q4	$89K	Buy	301 +176	+141%	+$64.2K	﹤0.01%	4786
2021 Q3	$48K	Buy	125 +42	+51%	+$16.6K	﹤0.01%	4750
2021 Q2	$43K	Buy	83 +35	+73%	+$22.3K	﹤0.01%	4895
2021 Q1	$27K	Sell	48 -28	-37%	-$18.6K	﹤0.01%	5068
2020 Q4	$52K	Buy	+76	New	+$37K	﹤0.01%	6009

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's ALGS Position: Q2 2026 in Review

Citigroup opened a new position in Aligos Therapeutics (ALGS) in Q2 2026: 1,808 shares worth $10.4K. The stake represents ﹤0.01% of the portfolio and ranks #5240 among its holdings. This is a return to the name: Citigroup previously reported a position in ALGS as recently as Q4 2025.

Citigroup first reported a position in ALGS in Q4 2020 and has held it in 11 quarters since. The position peaked at $89K in Q4 2021. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Citigroup held 1,808 shares of Aligos Therapeutics worth $10.4K as of Q2 2026.
Aligos Therapeutics was a new Citigroup position in Q2 2026.
Aligos Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5240 holding.
Citigroup first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 11 quarters since.
Citigroup's Aligos Therapeutics position peaked at $89K in Q4 2021.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.